Dawson James Starts Genprex (GNPX) at Buy

(Updated - January 30, 2023 7:46 AM EST)

Dawson James initiates coverage on Genprex (NASDAQ: GNPX) with a Buy rating and a price target of $3.00.

The analyst comments "We project our model out to 2033. We apply a 30% risk cut to our projected revenues in our product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models. We use a fully diluted out year share count assuming multiple raises. The result is equal-weighted and averaged and rounded to the nearest whole number to derive our 12-month projected price target of $3.00. We note that as the company established proof of concept as a result of clinical trial data, the risk rate (r) is reduced, and valuation rises."

For an analyst ratings summary and ratings history on Genprex click here. For more ratings news on Genprex click here.

Shares of Genprex closed at $1.34 yesterday.

You May Also Be Interested In

• Academy Sports and Outdoors (ASO) shares 'too inexpensive' claims Baird analyst
• Tongcheng-Elong (780:HK) PT Raised to HK$20.80 at Goldman Sachs
• H&H International Holdings (1112:HK) (BTSDF) PT Raised to HK$15.80 at HSBC